drugset / Trial / NCT01600612

Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial

NCT01600612

RandomizedParallel-groupOpen-labelTreatment

Summary

Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin. Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.

Timeline

Start
2012-09
Primary completion
2013-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbetocin Peptide 10 ug Intravenous
Comparator Misoprostol Other / unclassified 600 ug Other
Comparator Oxytocin Peptide 30 iu Intravenous

Indications

No indication recorded.